Indication-Based Pricing for Multi-Indication Drugs

被引:0
|
作者
Adida, Elodie [1 ]
机构
[1] Univ Calif Riverside, Sch Business, Riverside, CA 92521 USA
关键词
healthcare operations; drug pricing; indication-based pricing;
D O I
10.1287/mnsc.2022.01721
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
Many pharmaceutical drugs have multiple indications, for which they offer a varying degree of benefit for patients. Yet, in the current U.S. pricing system, the price of the drug is the same regardless of the indication for which it is prescribed. This uniform pricing policy can deter the payer from providing coverage for low-value indications, if the price is high relative to the potential benefit for patients, which can reduce patients' access to the drug. It can also deter the drug manufacturer from investing in obtaining U.S. Food and Drug Administration (FDA) approval for new indications, as the lack of flexibility in pricing can result in too low demand (and thus profits) to recoup fixed investment costs. Indication-based pricing has been proposed as a new pricing mechanism for multiindication drugs allowing the price to differ according to the indication, to better align the price of the drug to its value. In this paper, we analyze the effect of indication-based pricing in comparison with uniform pricing on the drug manufacturer's profit and investment incentives, the patient demand and utility, the payer's coverage incentives, and the payer's objective. Under uniform pricing, we consider both the cases when the price can versus cannot be adjusted upon introduction of a new indication. We find that the drug manufacturer earns higher profits under indication-based pricing than under uniform pricing. Moreover, indication-based pricing improves incentives for the manufacturer to invest in a new indication and for the payer to cover the drug. If the fixed investment cost is high, indication-based pricing also benefits patients and the payer's objective. Otherwise, the patient demand, patient utility and payer's objective may be lower under indication-based pricing. Hence, payers who value the patient utility should carefully consider the tradeoffs involved in implementing this pricing system and where the bottlenecks are under uniform pricing.
引用
收藏
页码:7506 / 7523
页数:19
相关论文
共 50 条
  • [41] Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
    Daniel Tobias Michaeli
    Mackenzie Mills
    Panos Kanavos
    [J]. Applied Health Economics and Health Policy, 2022, 20 : 757 - 768
  • [42] Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
    Michaeli, Daniel Tobias
    Mills, Mackenzie
    Kanavos, Panos
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (05) : 757 - 768
  • [43] Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
    Mackenzie Mills
    Panos Kanavos
    [J]. PharmacoEconomics - Open, 2023, 7 : 553 - 565
  • [44] Indication documentation and indication-based prescribing within electronic prescribing systems: a systematic review and narrative synthesis
    Feather, Calandra
    Appelbaum, Nicholas
    Darzi, Ara
    Franklin, Bryony Dean
    [J]. BMJ QUALITY & SAFETY, 2023, 32 (06) : 357 - 368
  • [45] Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
    Persson, Ulf
    Norlin, J. M.
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (02) : 157 - 165
  • [46] TRILO: A Traffic Indication-Based Downlink Communication Protocol for LoRaWAN
    Oh, Youngjune
    Lee, Jongwon
    Kim, Chong-Kwon
    [J]. WIRELESS COMMUNICATIONS & MOBILE COMPUTING, 2018,
  • [47] VOLUME VS VALUE: UNDERSTANDING THE PRICING DYNAMICS OF MULTI-INDICATION THERAPIES IN WEIGHTED-AVERAGE LIST PRICE MARKETS
    Gerhardt, M.
    Malliou-Najjar, K.
    Jansen, C.
    Kassenaar, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S260 - S260
  • [48] Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
    Ulf Persson
    J. M. Norlin
    [J]. Applied Health Economics and Health Policy, 2018, 16 : 157 - 165
  • [49] Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference
    Al-Badriyeh, Daoud
    Fahey, Michael
    Alabbadi, Ibrahim
    Al-Khal, Abdullatif
    Zaidan, Manal
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (12) : 2798 - 2810
  • [50] GENE THERAPIES: HOW WILL INDICATION-BASED PRICING AFFECT PATIENT ACCESS AND COST-CONTAINMENT MECHANISMS FOR PAYERS?
    Grosvenor, A.
    Ermacora, P.
    [J]. VALUE IN HEALTH, 2019, 22 : S420 - S420